Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia.

F Ravandi, C Arana Yi, J E Cortes, M Levis, S Faderl, G Garcia-Manero, E Jabbour, M Konopleva, S O'Brien, Z Estrov, G Borthakur, D Thomas, S Pierce, M Brandt, K Pratz, R Luthra, M Andreeff, H Kantarjian

Journal: Leukemia 2014;28(7):1543-5

PMID: 24487412

Free Full Text on PubMed Central View on PubMed

Abstract

Address: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Division of Hematological Malignancies, Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, MD, USA.; Division of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

DOI: 10.1038/leu.2014.54

Link outs

Free resources

Full Text Sources:

Medical:

https://medlineplus.gov/acutemyeloidleukemia.html

Other Literature Sources:

https://scite.ai/reports/24487412

Subscription / membership required

Full Text Sources:

MeSH Terms: Antineoplastic Combined Chemotherapy Protocols, Cytarabine, Humans, Idarubicin, Leukemia, Myeloid, Acute, Niacinamide, Phenylurea Compounds, Sorafenib, Treatment Outcome